/ /

Colleen E. McCarthy
Colleen McCarthy is a freelance writer based in the Cleveland area and a former editor of Optometry Times. She is a 2010 graduate of the University of Dayton with a degree in journalism.
Study finds children with residual amblyopia did not find an advantage with levodopa
A recent study of children ages 7 to 12 with residual amblyopia did not find an advantage with the use of levodopa compared with a placebo group, according to Michael X. Repka, MD, MBA.
Why are medications so expensive in the U.S.?
A recent in-depth report from Medscape took a look at the complex history and causes of skyrocketing drug prices in the United States.
One door vs. two door debate continues
The new rule in Tennessee has reignited a debate across the country about similar rules creating a separation—both physical and professional—between ODs and retail spaces.
Experts issue new vision screening recommendations for children ages 3 to 5 years
The National Expert Panel to the National Center for Children’s Vision and Eye Health at Prevent Blindness has issued new recommendations to provide an evidence-based approach to screening children from 36 months to 72 months old.
Many AMD supplements do not meet AREDS or AREDS2 standards
Many AMD supplements do not meet AREDS or AREDS2 standards
A study recently published in Ophthalmology found that nutritional supplements marketed to help treat age-related macular degeneration (AMD) may not be backed by scientific evidence.
Update: Actavis and Allergan leaders discuss merger deal
Actavis CEO Brent Saunders and Allergan CEO David Pyott discuss the recent acquisition deal between the two companies with industry media.
Our top five most popular stories of 2014
Check out our most-read stories of the whole year.
AMD treatment market to exceed $10 billion by 2023
According to a report from GlobalData, the age-related macular degeneration treatment market in the U.S., UK, Germany, France, Spain, Italy, and Japan will double in value from $5.1 billion in 2013 to $10.1 billion in 2023.
HIV drug may also treat AMD
A recent study published in Science found that drugs that have been used to treat HIV/AIDS for 30 years can also be used to treat age-related macular degeneration (AMD), as well as other inflammatory disorders, due to previously undiscovered intrinsic and inflammatory activity those drugs possess.
7 financial challenges that ODs will face in 2015
7 financial challenges that ODs will face in 2015
We recently asked some ODs what they think are the biggest challenges facing the profession in 2015 and beyond. Here’s our list of seven challenges—and we think all are important.